Immunocore Holdings plc Investing Cash Flow
Immunocore Holdings plc (IMCR) reported Investing Cash Flow of $3.43 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-06
- Immunocore Holdings plc net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$786.00K.
- Immunocore Holdings plc net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $4.22M, a 56.51% decline year-over-year.
- Immunocore Holdings plc net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$880.00K.
- Immunocore Holdings plc net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $5.25M.
- Immunocore Holdings plc net cash provided by (used in) investing activities for fiscal 2025 was -$16.34M.
- Immunocore Holdings plc net cash provided by (used in) investing activities for fiscal 2024 was -$355.13M.
- Immunocore Holdings plc net cash provided by (used in) investing activities for fiscal 2023 was -$5.42M.
- Immunocore Holdings plc net cash provided by (used in) investing activities for fiscal 2022 was -$2.20M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$786.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $3.43M 10-Q · filed 2026-08-06 | $2.55M derived: sum of 3 quarters · filed 2026-08-06 | $7.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $4.22M 10-Q · filed 2026-05-06 | $3.34M derived: sum of 2 quarters · filed 2026-05-06 | $8.59M derived: sum of 3 quarters · filed 2026-05-06 | -$21.82M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$880.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $4.37M derived: sum of 2 quarters · filed 2026-02-25 | -$26.04M derived: sum of 3 quarters · filed 2026-08-06 | -$16.34M 10-K · filed 2026-02-25 |
| 2025-09-30 | $5.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$25.16M derived: sum of 2 quarters · filed 2026-08-06 | -$15.46M 10-Q · filed 2025-11-06 | -$19.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$30.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$20.71M 10-Q · filed 2026-08-06 | -$24.25M derived: sum of 3 quarters · filed 2026-08-06 | -$25.08M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $9.70M 10-Q · filed 2026-05-06 | $6.16M derived: sum of 2 quarters · filed 2026-05-06 | $5.33M derived: sum of 3 quarters · filed 2026-05-06 | -$345.00M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$3.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$4.37M derived: sum of 2 quarters · filed 2026-02-25 | -$354.70M derived: sum of 3 quarters · filed 2026-02-25 | -$355.13M 10-K · filed 2026-02-25 |
| 2024-09-30 | -$828.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$351.16M derived: sum of 2 quarters · filed 2025-11-06 | -$351.59M 10-Q · filed 2025-11-06 | -$352.41M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | -$350.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$350.76M 10-Q · filed 2025-08-07 | -$351.58M derived: sum of 3 quarters · filed 2026-02-25 | -$351.79M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | -$430.00K 10-Q · filed 2025-05-07 | -$1.25M derived: sum of 2 quarters · filed 2026-02-25 | -$1.46M derived: sum of 3 quarters · filed 2026-02-25 | -$2.85M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | -$817.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$1.03M derived: sum of 2 quarters · filed 2026-02-25 | -$2.42M derived: sum of 3 quarters · filed 2026-02-25 | -$5.42M 10-K · filed 2026-02-25 |
| 2023-09-30 | -$212.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$1.61M derived: sum of 2 quarters · filed 2024-11-06 | -$4.61M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | -$1.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$4.40M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | -$3.00M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | -$2.20M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | -$1.28M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |